



Date: October 8, 2024

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051.

Scrip Code: STAR

The BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

Scrip Code: 532531

Dear Sir/Madam,

Subject: Newspaper Advertisement w.r.t notice of final hearing of Company Scheme Petition

Ref: Scheme of Arrangement amongst Strides Pharma Science Limited and Steriscience Specialties Private Limited and Onesource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) and their respective shareholders

We enclose herewith copy of the newspaper advertisement published in Business Standard (English) and Navshakti (Marathi) on October 8, 2024 regarding Notice of petition fixed for final hearing before the Hon'ble National Company Law Tribunal, Mumbai Bench ('NCLT') on October 25, 2024 in the matter of Scheme of Arrangement amongst Strides Pharma Science Limited ("Petitioner Company 1" or "Transferor Company 1" or "Demerged Company 1" or "Company") and Steriscience Specialties Private Limited ("Petitioner Company 2" or "Transferor Company 2" or "Demerged Company 2") and Onesource Specialty Pharma Limited (formerly known as "Stelis Biopharma Limited") ("Petitioner Company 3" or "Transferee Company" or "Resulting Company") and their respective shareholders ("Scheme")

A copy of the said advertisement will also be made available on the Company's website at www.strides.com.

This is for your information and records.

Thanks & regards.

For & On behalf of
Strides Pharma Science Limited

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515
Address: Sumukha Maple Grove,
Akshay Nagar, Bangalore - 560068

Enclosures:

- i) Copy of newspaper advertisement published in Business Standard (English) and Navshakti (Marathi) dated October 8, 2024.

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942
corpcomm@strides.com, www.strides.com

Orders, input costs to keep cap goods on rails

Brokerages predict 12-22% revenue growth, 13-18% rise in Ebitda

AMRITHA PILLAY
Mumbai, 7 October

Brokerage firms estimate that the capital goods sector will report double-digit growth in revenue and earnings for the July-September quarter (Q3) of 2024-25 (FY25). They noted that raw material prices have continued to ease over the past three months, while new order wins have increased.

Three brokerages — Motilal Oswal, Kotak, and Elara Capital — estimate revenue growth from 12 per cent to 22 per cent for Q3FY25. They expect earnings before interest, tax, depreciation, and amortisation to rise by 13-18 per cent year-on-year (Y-o-Y) for their respective capital goods coverage.

Elara Capital highlights strong industrial demand and robust execution, supported by a healthy order backlog, as the main drivers of an expected 14 per cent Y-o-Y growth in sales.


Elara analysts noted that major capital goods companies, excluding Larsen & Toubro (L&T), announced cumulative orders worth ₹79,300 crore in Q2FY25, up 182 per cent from a year ago. L&T, according to BSE disclosures, announced orders worth up to ₹47,500 crore during the same period.

In a Bloomberg poll, six analysts estimated L&T's revenue at ₹56,652 crore, while three analysts projected a net adjusted profit of ₹2,558 crore for India's largest engineering conglomerate. While healthy order book execution is expected to drive revenue growth in Q3FY25, analysts believe margins will remain stable due to benign raw material prices.

Regarding margins, Motilal Oswal analysts expect them to remain within a stable range, citing benign commodity prices, cost-saving measures, and an improved pro-



ROBUST GROWTH



duct mix. Copper prices have eased by 2 per cent, aluminium by 4 per cent, and zinc has remained flat in recent months compared to the start of the first quarter of FY25. "Accordingly, we expect a 30-basis-point Y-o-Y margin expansion in Q3FY25 for our coverage universe," they said.

However, gains from the recent easing of input costs may vary across different sub-segments of the capital goods sector. In a response to Business Standard last month, Ashish Modani, senior vice-president and co-group head of corporate ratings at Investment Information and Credit Rating Agency (ICRA), explained, "Long-term construction projects (over 18-24 months) generally have a commodity index-linked

price variation clause, where both increases and decreases in commodity prices are passed on to the customer or project-awarding authority."

He added, "Construction entities working in segments like industrial projects or warehouse construction typically have fixed-price contracts due to their shorter duration. These engineering, procurement, and construction entities may benefit from the moderation in commodity prices in the near term."

Kotak analysts, however, offer a different view, stating, "Meaningful benefits from declining steel prices are expected to impact the second half of FY25." They also noted the possibility of a sequential contraction in margins "to reflect the normalisation of benefits from lower raw material prices across the motor spectrum", including companies like Siemens, ABB, and CG Power.



Q2
RESULT
PREVIEW

Regarding margins, Motilal Oswal analysts expect them to remain within a stable range, citing benign commodity prices, cost-saving measures, and an improved pro-

(Continue from previous page...)

- for tendering and settlement of shares under the revised mechanism is specified in the Annexure to the said circular.
5) BSE Limited, Mumbai ("BSE") will be the Stock Exchange for the purpose of tendering the Equity shares in the Open Offer.
6) The Acquirer will appoint a registered broker as a Buying Broker for the purpose of this Open Offer through whom the purchases and settlements on account of the Offered Shares tendered during the tendering period under this Open Offer will be made.
7) All Public Shareholders who desire to tender their Equity Shares under the Offer would have to intimate their respective stock brokers ("Selling Broker") within the normal trading hours of the secondary market, during the Tendering Period.
8) A separate Acquisition Window will be provided by BSE to facilitate the placing of orders. The Selling Broker would be required to place an order / bid on behalf of the Public Shareholders who wish to tender Equity Shares in the Open Offer using the Acquisition Window of the BSE. Before placing the order/bid, the Selling Broker will be required to mark len on the tendered Equity Shares. Details of such Equity Shares marked as len in the demat account of the Public Shareholders shall be provided by the depositary to the Indian Clearing Corporation ("Clearing Corporation").
9) As per the provisions of Regulation 40(1) of the SEBI (LODR) Regulations, 2015 and SEBI's press release dated December 03, 2018, bearing reference no. PR 49/2018, requests for transfer of securities shall not be processed unless the securities are held in dematerialised form with a depository with effect from April 01, 2019. However, in accordance with the circular issued by SEBI bearing reference number SEBI/HO/CFD/

CMD1/CIR/P/2020/144 dated July 31, 2020, shareholders holding securities in physical form are allowed to tender shares in an open offer. Such tendering shall be as per the provisions of the SEBI (SAST) Regulations, 2011. Accordingly, Public Shareholders holding Equity Shares in physical form as well are eligible to tender their Equity Shares in this Open Offer as per the provisions of the SEBI (SAST) Regulations, 2011.
10) Equity Shares should not be submitted/tendered to the Manager to the Open Offer, the Acquirer or the Target Company.
IX. THE DETAILED PROCEDURE FOR TENDERING THE SHARES IN THE OFFER WILL BE AVAILABLE IN THE LETTER OF OFFER, WHICH SHALL BE AVAILABLE ON THE WEBSITE OF SEBI (WWW.SEBI.GOV.IN).
X. OTHER INFORMATION:
1) For the purpose of disclosures in this DPS relating to the Target Company, the Acquirer has relied upon the publicly available information and information provided by the Target Company and has not independently verified the accuracy of details of the Target Company. Subject to the aforesaid, the Acquirer accepts the responsibility for the information contained in the DPS and also for the obligations of the Acquirer laid down in the SEBI (SAST) Regulations, 2011.
2) Pursuant to Regulation 12 of the SEBI (SAST) Regulations, 2011, the Acquirer has appointed Mark Corporate Advisors Private Limited as Manager to the Open Offer.
3) The Acquirer has appointed Venture Capital and Corporate Investments Private Limited, as Registrar to the Offer having Registered Office at Aurum, Plot No. 57, 5th Floor, Jayabheri Enclave, Phase-II, Gachibowli, Hyderabad-500 032, Telangana, Contact No.: +91 40 2381 8475/3516 9490, Email ID: pvsrinivas@vcclp.com, Investor Grievance Email ID: investor.relations@vcclp.com; Contact Person: Mr. P V Srinivas Rao, SEBI

Reg. No.: INR000001203.
In this DPS, any discrepancy in any table between the total and sums of the amount listed is due to rounding off and/or regrouping.
5) This DPS and the PA will also be available on the website of SEBI i.e., www.sebi.gov.in.
Issued by Manager to the Offer:
MARK CORPORATE ADVISORS PRIVATE LIMITED
CIN: U67190MH2008PTC181996
404/1, The Summit Business Bay, Sant Janabai Road (Service Lane),
Off Western Express Highway, Vile Parle (East), Mumbai - 400 057.
Contact Person: Mr. Manish Gaur | Tel. No.: +91 22 2612 3207/08
Email ID: openoffer@markcorporateadvisors.com
Investor Grievance Email ID: investorgrievance@markcorporateadvisors.com
SEBI Registration No.: INM000012128

lakh are not eligible. Individuals from families with government employees are not eligible.

Types of internships:
Internships will be available across various sectors, including information technology, banking, healthcare, agriculture and other industries represented by the top 500 companies in India.

COMPILED BY AYUSH MISHRA

Love bungee jumping? Take cover before your next adventure trip

HIMALI PATEL

Magma HDI General Insurance recently announced the launch of OneProtect, a personal accident (PA) cover with over 20 customisable add-ons that customers can purchase according to their needs. The timing of the launch is apt, given that the festive period of Navratri, Dussehra, and Diwali has begun when the risk of fire and other accidents increases.

This is also a time when people embark on holidays that

include adventure sports. "Accidents are unpredictable, whether it's a mishap during Diwali or Dussehra, a fracture during travel, or a fall in the bathroom," says Amit Bhandari, chief technical officer, Magma HDI General Insurance.

A PA cover can help in such circumstances. "A typical health insurance policy does not cover injuries or accidents during sports like scuba diving or paragliding," says Naval Goel, founder and chief executive officer (CEO), PolicyX.com.

Coverage gaps a PA policy fills

A PA cover differs from term and medical insurance. Bhandari explains that a term policy essentially covers death. Even if it includes a personal accident rider, it often comes with exclusions, such as adventure sports.

A medical cover may handle medical expenses but does not provide for the temporary or permanent loss of income during the recovery period and after, and expenditures such as travel costs incurred by family members.

"A PA policy, however, covers not only accidental death but also permanent total disability, permanent partial disability, and temporary total disability, along with other possible loss-related scenarios during accidents," says Shashi Kant Dahuja, executive director and chief underwriting officer, Shriram General Insurance.

"If you take an adventure sports cover along with the PA policy, the premium for a ₹25-50 lakh sum insured can come to ₹20,000-25,000 a year. A cover of over ₹50 lakh may mean an annual premium of ₹30,000-1 lakh," says Goel.

Must-have covers and add-ons

PA policies come with a variety of add-ons. Bhandari recommends add-ons such as parental care, widowhood cover, child education support, and a marriage fund for children.

Dahuja suggests covers for broken bones, outpatient department (OPD) fee, burns, coma, emergency family travel, and funerals.

Goel highlights the importance of including coverage for loss of income due to temporary or permanent disability.

"In case of disability, benefits like crutches, wheelchairs, arti-

PRICE OF PROTECTION AGAINST ACCIDENTS

Premiums are for a 40-year-old male for a sum insured of ₹50 lakh

Plan	Annual premium (₹)
Aditya Birla personal accident cover	3,409
Star Health personal accident policy	4,130
Manipal Cigna personal accident policy	5,428
Niva Bupa personal accident cover	6,790
Care Health personal accident cover	12,617

Besides general insurers, health insurers too offer personal accident covers

Source: PolicyX.com

PM internship scheme: How much will you be paid? And how to apply?

Over 2,200 internship opportunities have been listed on the portal for the Prime Minister internship scheme. If selected, applicants will get a monthly stipend of ₹4,500 from the government, and an additional ₹500 by companies as part of their corporate social responsibility (CSR) initiatives.

Eligibility criteria

To qualify for the Prime Minister internship scheme, applicants must meet the following requirements:
Age: Between 21 and 24 years old.

Employment status:

Must not be engaged in full-time employment.

Educational background:

At least Class 10. Graduates from

Read full report here: mybs.in/2dZeGml

premier institutions (like IITs and IIMs) or those with professional qualifications (like CA or CMA) are excluded. The scheme is also open to youth trained at Industrial Training Institutes (ITIs) and Kausal Kendras (skill centres).

Income restrictions:

Individuals from families with annual incomes exceeding ₹8

lakh are not eligible. Individuals from families with government employees are not eligible.

Types of internships:
Internships will be available across various sectors, including information technology, banking, healthcare, agriculture and other industries represented by the top 500 companies in India.

COMPILED BY AYUSH MISHRA

Form No. – NCLT 3A
(Rule 35 of the National Company Law Tribunal Rules, 2016)
Before The National Company Law Tribunal, Allahabad Bench
Company Petition No. CP (CAA) No. 16/ALD/2024
In Connection With Company Application No. CA (CAA) No. 04/ALD/2024

In the matter of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with Companies (Compromises, Arrangements and Amalgamations) Rules, 2016
And

In the matter of Scheme of Arrangement between Umang Dairies Limited, Panchmahal Properties Limited and Bengal & Assam Company Limited and their respective shareholders and creditors

Umang Dairies Limited [CIN: L15111UP1992PLC014942], a Public Limited Company incorporated under the Companies Act, 1956, and having its registered office at Gajraula Hasanpur Road, 3 Km Stone, Dist. Jyoti Phule Nagar, Amroha, Gajraula, Uttar Pradesh – 244 233
And

Panchmahal Properties Limited [CIN: U74899UP1995PLC189056], a Public Limited Company, incorporated under Companies Act, 1956 having its registered office at 3 Km Stone, Hasanpur Road, Gajraula, Jyoti Phule Nagar, Hasanpur, Uttar Pradesh – 244 235

...Hereinafter Referred to as Petitioner Companies

NOTICE OF HEARING OF PETITION

A petition under Sections 230-232 of Companies Act, 2013 (Petition) seeking sanction of the proposed Scheme of Arrangement between Umang Dairies Limited, Panchmahal Properties Limited and Bengal & Assam Company Limited and their respective shareholders & creditors, was presented by the Petitioner Companies before the Allahabad Bench of Hon'ble National Company Law Tribunal (NCLT) on 20th September, 2024, and was admitted by the Hon'ble NCLT. Hon'ble NCLT vide its order dated 20th September, 2024 has fixed 7th November, 2024 as the date of hearing of the Petition.

Any person desirous of supporting or opposing the said Petition should send to Petitioner Companies, at the address mentioned above, a notice of his / her intention, signed by him / her or by his / her advocate, with his / her name and address, and to the Hon'ble NCLT at 6/7-B, Fanna Lal Road, Prayagraj – 211 002, so as to reach the Petitioner Companies not later than two days before the date fixed for hearing of the petition i.e. 7th November, 2024. Any person who seeks to oppose the Petition, the grounds of opposition or a copy of his / her affidavit, shall be furnished with such notice. A copy of the Petition will be furnished by the Petitioner Companies to any person requiring the same, on payment of the prescribed charges.

For Umang Dairies Limited For Panchmahal Properties Limited
Sd/-
Pankaj Kamra
Company Secretary
Dillip Kumar Swain
Authorised Signatory
Date: 7th October, 2024

BEFORE THE NATIONAL COMPANY LAW TRIBUNAL MUMBAI BENCH
C.P.(CAA)/172/MB/2024
IN
C.A.(CAA)/118/MB/2024
In the matter of the Companies Act, 2013;
AND

In the matter of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules framed thereunder
AND

In the matter of Scheme of Arrangement amongst Strides Pharma Science Limited ("Petitioner Company 1" or "Transferee Company 1" or "Demerged Company 1") and Sterisience Specialties Private Limited ("Petitioner Company 2" or "Transferee Company 2" or "Demerged Company 2") and Onesource Specialty Pharma Limited (Formerly known as "Stelis Biopharma Limited") ("Petitioner Company 3" or "Transferee Company" or "Residual Company") and their respective Shareholders ("Scheme" or the "Scheme of Arrangement")

Strides Pharma Science Limited, a Public Limited Listed Company incorporated under the provisions of Companies Act, 1956, having its registered office at 201, Devavrat, Sector 17, Vashi, Navi Mumbai - 400703, Maharashtra, India CIN: L24230MH1990PLC057062

Sterisience Specialties Private Limited, a Company incorporated under the provisions of Companies Act, 2013, having its registered office at 201, Devavrat, Sector 17, Vashi, Navi Mumbai - 400703, Maharashtra, India CIN: U24304MH2020PTC424881

Onesource Specialty Pharma Limited, a Company incorporated under the provisions of Companies Act, 1956, having its registered office at 201, Devavrat, Sector 17, Vashi, Navi Mumbai - 400703, Maharashtra, India CIN: U74714MH2007PLC432497

(Collectively referred to as "Petitioner Companies")

NOTICE OF PETITION
A Petition under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 for the sanction of Scheme of Arrangement amongst Strides Pharma Science Limited and Sterisience Specialties Private Limited and Onesource Specialty Pharma Limited (Formerly known as "Stelis Biopharma Limited") and their respective Shareholders presented by the Petitioner Companies before the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") was admitted by the Hon'ble NCLT on 25th September

